University of California-San Francisco · NeuroscienceCognition Care Lab
Peter Alexander Ljubenkov · San Francisco, California
Research Focus
Dr. Peter Alexander Ljubenkov's lab focuses on finding new treatments for patients with semantic variant primary progressive aphasia (svPPA), a form of dementia closely linked to frontotemporal lobar degeneration. They are conducting a clinical trial to test a drug called Verdiperstat, which may help address the underlying causes of this condition. The lab aims to gather important information about how the drug works and its safety in patients, contributing to future therapies for cognitive disorders related to neurodegeneration.
semantic variant primary progressive aphasiafrontotemporal dementiapharmacodynamicsclinical trialsneurodegeneration
Research Aims
3AIM 01Investigate the safety and tolerability of Verdiperstat in patients with svPPA.
AIM 02Assess the pharmacokinetics of Verdiperstat in blood and cerebrospinal fluid.
AIM 03Explore the effects of Verdiperstat on biomarkers of neurodegeneration.
Skills the Lab Values
clinical trial designrandomized controlled trialspharmacokineticsbiomarker analysispatient recruitment
Output against the department
Publications84bottom 25% of dept.501st of 671
this lab
most publishedleast published
Citations1.8kbottom 10% of dept.603rd of 671
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.